시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 혈관활성 장 펩타이드 종양 시장 보고서(2025년)
Vasoactive Intestinal Peptide Tumor Global Market Report 2025
상품코드 : 1751159
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,170,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,918,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,666,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

혈관활성 장 펩타이드 종양 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 연평균 6.3%의 CAGR로 20억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 화학요법에 대한 수요 증가, 약물 승인 가속화, 경구용 약물에 대한 선호도 증가, 질병에 대한 인식 증가, 종양 유병률 증가 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 표적 치료의 발전, 진단 기술 향상, 혁신적 치료법 개발, 맞춤형 의료의 부상, 새로운 치료 솔루션 출시 등을 들 수 있습니다.

표적 치료의 채택 확대는 혈관활성 장 펩타이드(VIP) 종양 시장의 성장을 견인할 것으로 예상됩니다. 표적 치료는 질병, 특히 암의 발생과 진행에 관여하는 특정 분자나 경로에 작용하도록 설계되어 건강한 세포를 보존하면서 비정상적인 세포를 선택적으로 제거할 수 있습니다. 이러한 표적 치료의 증가는 특정 유전자 변이를 표적으로 삼고 부작용을 최소화하여 치료 효과를 향상시키는 정밀 의학의 발전으로 촉진되고 있으며, VIP 종양의 경우 표적 치료는 종양의 성장과 호르몬 분비에 관여하는 중요한 경로를 억제하여 효과를 발휘합니다. 이를 통해 VIP 수치를 낮추고, 심한 설사 등의 증상을 완화하며, 질병의 진행을 늦출 수 있습니다. 예를 들어, 2024년 7월 미국 유전자세포 치료학회(ASGCT)는 2024년 2분기에 76건의 유전자 치료 임상시험이 시작되어 전분기 대비 25% 증가했다고 보고했습니다. 이처럼 표적 치료제의 이용 확대가 VIP 종양 시장 확대에 박차를 가하고 있습니다.

신경내분비종양 유병률의 증가는 혈관활성 장 펩타이드 종양 시장을 견인할 것으로 예상됩니다. 신경내분비종양(NET)은 신경과 호르몬을 생산하는 두 가지 기능을 모두 가진 세포에서 발생하는 희귀한 후발성 암입니다. 이환율의 증가는 진단 방법의 발전으로 이전에는 과소 진단되었던 종양을 더 일찍, 더 정확하게 식별할 수 있게 되었기 때문이며, NET의 희귀한 하위 집합인 VIP 종양은 VIP의 과다 분비가 특징이며, 심한 수양성 설사와 전해질 균형 장애를 유발합니다. 예를 들어, 정부 기관인 Cancer Australia가 2024년 9월에 발표한 바에 따르면, 85세까지 신경내분비종양으로 진단받을 평생 위험은 약 55명 중 1명, 즉 1.8%를 기록할 것으로 예상됩니다. 이 위험은 여성(58명 중 1명, 1.7%)에 비해 남성(52명 중 1명, 1.9%)이 약간 더 높습니다. 따라서 신경내분비종양 발생률의 증가는 VIP 종양 시장의 성장에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

A vasoactive intestinal peptide (VIP) tumor, also known as a VIPoma, is a rare type of neuroendocrine tumor that most commonly originates in the pancreas. It produces excessive amounts of VIP, resulting in symptoms such as profuse watery diarrhea, dehydration, and electrolyte imbalances. Diagnosis is confirmed through elevated VIP levels in the blood, with treatment options including surgery, medications, and targeted therapies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary treatment approaches for vasoactive intestinal peptide tumors include surgical intervention, radiotherapy, chemotherapy, and targeted therapy. Surgical intervention focuses on safely removing localized tumors, alleviating symptoms, and preventing complications, either through complete or minimally invasive resection. Diagnosis is carried out using various methods such as imaging techniques, biopsy, and endoscopic ultrasound. Therapeutic strategies include palliative care, curative treatment, and adjuvant therapy. These treatments are utilized across a range of end-user settings, including hospitals, cancer specialty clinics, and diagnostic laboratories.

The vasoactive intestinal peptide tumor market research report is one of a series of new reports from The Business Research Company that provides vasoactive intestinal peptide tumor market statistics, including the vasoactive intestinal peptide tumor industry global market size, regional shares, competitors with the vasoactive intestinal peptide tumor market share, detailed vasoactive intestinal peptide tumor market segments, market trends, and opportunities, and any further data you may need to thrive in the vasoactive intestinal peptide tumor industry. This vasoactive intestinal peptide tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vasoactive intestinal peptide tumor market size has grown strongly in recent years. It will grow from$1.51 billion in 2024 to $1.61 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to the rising prevalence of VIP tumors, increased emphasis on research and development activities, growing healthcare awareness, the expansion of healthcare infrastructure, and enhanced collaborations between biotechnology companies and research institutions.

The vasoactive intestinal peptide tumor market size is expected to see strong growth in the next few years. It will grow to$2.05 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth during the forecast period can be attributed to the rising demand for chemotherapy, accelerated drug approvals, growing preference for oral medications, increased disease awareness, and the increasing prevalence of tumors. Key trends in the forecast period include advancements in targeted therapies, improvements in diagnostic techniques, the development of innovative treatment options, the rise of personalized medicine, and the launch of novel therapeutic solutions.

The increasing adoption of targeted therapy is anticipated to drive the growth of the vasoactive intestinal peptide (VIP) tumor market. Targeted therapies are designed to act on specific molecules or pathways involved in the development and progression of diseases, especially cancer, enabling the selective elimination of abnormal cells while sparing healthy ones. This rise in targeted therapies is fueled by advancements in precision medicine, which improve treatment effectiveness by targeting specific genetic mutations and minimizing adverse effects. In the case of VIP tumors, targeted therapies work by inhibiting critical pathways responsible for tumor growth and hormone secretion. This reduces VIP levels, alleviates symptoms such as intense diarrhea, and slows disease progression. For example, in July 2024, the American Society of Gene and Cell Therapy (ASGCT), a U.S.-based professional organization, reported that 76 gene therapy trials were initiated in the second quarter of 2024, a 25% increase compared to the previous quarter. Thus, the growing use of targeted therapy is fueling the expansion of the VIP tumor market.

The growing prevalence of neuroendocrine tumors is expected to boost the vasoactive intestinal peptide tumor market. Neuroendocrine tumors (NETs) are uncommon, slow-developing cancers originating from cells that have both nerve and hormone-producing functions. Their rising incidence is attributed to advancements in diagnostic methods, which allow for earlier and more precise identification of tumors that were previously underdiagnosed. VIP tumors, a rare subset of NETs, are marked by excessive secretion of VIP, leading to severe watery diarrhea and disturbances in electrolyte balance. For instance, in September 2024 by Cancer Australia, a government agency, the lifetime risk of being diagnosed with neuroendocrine tumors by age 85 is about 1 in 55, or 1.8%. This risk is slightly higher in males (1 in 52 or 1.9%) compared to females (1 in 58 or 1.7%). Therefore, the rising incidence of neuroendocrine tumors is contributing to the growth of the VIP tumor market.

Leading companies in the vasoactive intestinal peptide tumor market are investing in the development of innovative products, including long-acting injectable suspensions, to enhance treatment efficacy, boost patient adherence, and offer prolonged symptom control. These formulations gradually release the active ingredient over time, reducing the frequency of administration. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., a U.S.-based pharmaceutical firm, introduced the first generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the United States. This drug is used for long-term therapy in acromegaly patients who have not responded adequately to surgery or radiation. It also treats severe diarrhea and flushing associated with metastatic carcinoid tumors and VIP-secreting tumors. The launch highlights Teva's capabilities in developing complex generics and supports its strategy of maintaining a solid foothold in the generic drug market.

Major players in the vasoactive intestinal peptide tumor market are Pfizer Inc., Novartis AG, Mayo Clinic, Labcorp Holdings Inc., Mount Sinai Hospital, Cleveland Clinic Laboratories, Penn Medicine, Stanford Health Care, UCSF Health, ARUP Laboratories, Dr. Lal PathLabs, Cancer Research UK, Medicover Hospitals, NuView Life Sciences Inc., DNA Labs India, Inter Science Institute, Ulta Lab Tests, True Health Labs, Ganesh Diagnostic, and Agilus Diagnostics.

North America was the largest region in the vasoactive intestinal peptide tumor market in 2024. The regions covered in vasoactive intestinal peptide tumor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vasoactive intestinal peptide tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vasoactive intestinal peptide tumor market consists of revenues earned by entities by providing services such as genetic testing, immunotherapy, hormone therapy, nuclear medicine, personalized medicine, palliative care, clinical trials, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasoactive intestinal peptide (VIP) Tumor market also includes sales of diagnostic kits, biopsy needles, imaging systems, radiation therapy equipment, chemotherapy drugs, targeted therapy drugs, surgical instruments, and supportive care medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vasoactive Intestinal Peptide Tumor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vasoactive intestinal peptide tumor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for vasoactive intestinal peptide tumor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vasoactive intestinal peptide tumor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Vasoactive Intestinal Peptide Tumor Market Characteristics

3. Vasoactive Intestinal Peptide Tumor Market Trends And Strategies

4. Vasoactive Intestinal Peptide Tumor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Vasoactive Intestinal Peptide Tumor Growth Analysis And Strategic Analysis Framework

6. Vasoactive Intestinal Peptide Tumor Market Segmentation

7. Vasoactive Intestinal Peptide Tumor Market Regional And Country Analysis

8. Asia-Pacific Vasoactive Intestinal Peptide Tumor Market

9. China Vasoactive Intestinal Peptide Tumor Market

10. India Vasoactive Intestinal Peptide Tumor Market

11. Japan Vasoactive Intestinal Peptide Tumor Market

12. Australia Vasoactive Intestinal Peptide Tumor Market

13. Indonesia Vasoactive Intestinal Peptide Tumor Market

14. South Korea Vasoactive Intestinal Peptide Tumor Market

15. Western Europe Vasoactive Intestinal Peptide Tumor Market

16. UK Vasoactive Intestinal Peptide Tumor Market

17. Germany Vasoactive Intestinal Peptide Tumor Market

18. France Vasoactive Intestinal Peptide Tumor Market

19. Italy Vasoactive Intestinal Peptide Tumor Market

20. Spain Vasoactive Intestinal Peptide Tumor Market

21. Eastern Europe Vasoactive Intestinal Peptide Tumor Market

22. Russia Vasoactive Intestinal Peptide Tumor Market

23. North America Vasoactive Intestinal Peptide Tumor Market

24. USA Vasoactive Intestinal Peptide Tumor Market

25. Canada Vasoactive Intestinal Peptide Tumor Market

26. South America Vasoactive Intestinal Peptide Tumor Market

27. Brazil Vasoactive Intestinal Peptide Tumor Market

28. Middle East Vasoactive Intestinal Peptide Tumor Market

29. Africa Vasoactive Intestinal Peptide Tumor Market

30. Vasoactive Intestinal Peptide Tumor Market Competitive Landscape And Company Profiles

31. Vasoactive Intestinal Peptide Tumor Market Other Major And Innovative Companies

32. Global Vasoactive Intestinal Peptide Tumor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vasoactive Intestinal Peptide Tumor Market

34. Recent Developments In The Vasoactive Intestinal Peptide Tumor Market

35. Vasoactive Intestinal Peptide Tumor Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기